Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 46

1.

Quaking orchestrates a post-transcriptional regulatory network of endothelial cell cycle progression critical to angiogenesis and metastasis.

Azam SH, Porrello A, Harrison EB, Leslie PL, Liu X, Waugh TA, Belanger A, Mangala LS, Lopez-Berestein G, Wilson HL, McCann JV, Kim WY, Sood AK, Liu J, Dudley AC, Pecot CV.

Oncogene. 2019 Mar 27. doi: 10.1038/s41388-019-0786-6. [Epub ahead of print]

PMID:
30918328
2.

Endothelial miR-30c suppresses tumor growth via inhibition of TGF-β-induced Serpine1.

McCann JV, Xiao L, Kim DJ, Khan OF, Kowalski PS, Anderson DG, Pecot CV, Azam SH, Parker JS, Tsai YS, Wolberg AS, Turner SD, Tatsumi K, Mackman N, Dudley AC.

J Clin Invest. 2019 Mar 11;130:1654-1670. doi: 10.1172/JCI123106. eCollection 2019 Mar 11.

3.

Phase II study of stereotactic radiosurgery for the treatment of patients with oligoprogression on erlotinib.

Weiss J, Kavanagh B, Deal A, Villaruz L, Stevenson J, Camidge R, Borghaei H, West J, Kirpalani P, Morris D, Lee C, Pecot CV, Zagar T, Stinchcombe T, Pennell N.

Cancer Treat Res Commun. 2019;19:100126. doi: 10.1016/j.ctarc.2019.100126. Epub 2019 Feb 26.

PMID:
30852467
4.

Suppression of Myeloid Cell Arginase Activity leads to Therapeutic Response in a NSCLC Mouse Model by Activating Anti-Tumor Immunity.

Miret JJ, Kirschmeier P, Koyama S, Zhu M, Li YY, Naito Y, Wu M, Malladi VS, Huang W, Walker W, Palakurthi S, Dranoff G, Hammerman PS, Pecot CV, Wong KK, Akbay EA.

J Immunother Cancer. 2019 Feb 6;7(1):32. doi: 10.1186/s40425-019-0504-5.

5.

KRAS Suppression-Induced Degradation of MYC Is Antagonized by a MEK5-ERK5 Compensatory Mechanism.

Vaseva AV, Blake DR, Gilbert TSK, Ng S, Hostetter G, Azam SH, Ozkan-Dagliyan I, Gautam P, Bryant KL, Pearce KH, Herring LE, Han H, Graves LM, Witkiewicz AK, Knudsen ES, Pecot CV, Rashid N, Houghton PJ, Wennerberg K, Cox AD, Der CJ.

Cancer Cell. 2018 Nov 12;34(5):807-822.e7. doi: 10.1016/j.ccell.2018.10.001.

PMID:
30423298
6.

Immunotherapy combinations emerging in non-small-cell lung cancer.

Chao YL, Pecot CV.

Immunotherapy. 2018 Jun;10(8):627-629. doi: 10.2217/imt-2018-0046. No abstract available.

PMID:
29882690
7.

A survey of microRNA single nucleotide polymorphisms identifies novel breast cancer susceptibility loci in a case-control, population-based study of African-American women.

Bensen JT, Graff M, Young KL, Sethupathy P, Parker J, Pecot CV, Currin K, Haddad SA, Ruiz-Narváez EA, Haiman CA, Hong CC, Sucheston-Campbell LE, Zhu Q, Liu S, Yao S, Bandera EV, Rosenberg L, Lunetta KL, Ambrosone CB, Palmer JR, Troester MA, Olshan AF.

Breast Cancer Res. 2018 Jun 5;20(1):45. doi: 10.1186/s13058-018-0964-4.

8.

Factor XIIIA-expressing inflammatory monocytes promote lung squamous cancer through fibrin cross-linking.

Porrello A, Leslie PL, Harrison EB, Gorentla BK, Kattula S, Ghosh SK, Azam SH, Holtzhausen A, Chao YL, Hayward MC, Waugh TA, Bae S, Godfrey V, Randell SH, Oderup C, Makowski L, Weiss J, Wilkerson MD, Hayes DN, Earp HS, Baldwin AS, Wolberg AS, Pecot CV.

Nat Commun. 2018 May 18;9(1):1988. doi: 10.1038/s41467-018-04355-w.

9.

Targeting Accessories to the Crime: Nanoparticle Nucleic Acid Delivery to the Tumor Microenvironment.

Harrison EB, Azam SH, Pecot CV.

Front Pharmacol. 2018 Apr 4;9:307. doi: 10.3389/fphar.2018.00307. eCollection 2018. Review.

10.

Incorporating Pericytes into an Endothelial Cell Bead Sprouting Assay.

Azam SH, Smith M, Somasundaram V, Pecot CV.

J Vis Exp. 2018 Feb 16;(132). doi: 10.3791/57309.

11.

Correction: miR-509-3p is clinically significant and strongly attenuates cellular migration and multi-cellular spheroids in ovarian cancer.

Pan Y, Robertson G, Pedersen L, Lim E, Hernandez-Herrera A, Rowat AC, Patil SL, Chan CK, Wen Y, Zhang X, Basu-Roy U, Mansukhani A, Chu A, Sipahimalani P, Bowlby R, Brooks D, Thiessen N, Coarfa C, Ma Y, Moore RA, Schein JE, Mungall AJ, Liu J, Pecot CV, Sood AK, Jones SJ, Marra MA, Gunaratne PH.

Oncotarget. 2017 Mar 7;8(10):17406. doi: 10.18632/oncotarget.15921. No abstract available.

12.

Mediating Passive Tumor Accumulation through Particle Size, Tumor Type, and Location.

Perry JL, Reuter KG, Luft JC, Pecot CV, Zamboni W, DeSimone JM.

Nano Lett. 2017 May 10;17(5):2879-2886. doi: 10.1021/acs.nanolett.7b00021. Epub 2017 Apr 11.

13.

Combining Anti-Mir-155 with Chemotherapy for the Treatment of Lung Cancers.

Van Roosbroeck K, Fanini F, Setoyama T, Ivan C, Rodriguez-Aguayo C, Fuentes-Mattei E, Xiao L, Vannini I, Redis RS, D'Abundo L, Zhang X, Nicoloso MS, Rossi S, Gonzalez-Villasana V, Rupaimoole R, Ferracin M, Morabito F, Neri A, Ruvolo PP, Ruvolo VR, Pecot CV, Amadori D, Abruzzo L, Calin S, Wang X, You MJ, Ferrajoli A, Orlowski R, Plunkett W, Lichtenberg TM, Davuluri RV, Berindan-Neagoe I, Negrini M, Wistuba II, Kantarjian HM, Sood AK, Lopez-Berestein G, Keating MJ, Fabbri M, Calin GA.

Clin Cancer Res. 2017 Jun 1;23(11):2891-2904. doi: 10.1158/1078-0432.CCR-16-1025. Epub 2016 Nov 30.

14.

FAK regulates platelet extravasation and tumor growth after antiangiogenic therapy withdrawal.

Haemmerle M, Bottsford-Miller J, Pradeep S, Taylor ML, Choi HJ, Hansen JM, Dalton HJ, Stone RL, Cho MS, Nick AM, Nagaraja AS, Gutschner T, Gharpure KM, Mangala LS, Rupaimoole R, Han HD, Zand B, Armaiz-Pena GN, Wu SY, Pecot CV, Burns AR, Lopez-Berestein G, Afshar-Kharghan V, Sood AK.

J Clin Invest. 2016 May 2;126(5):1885-96. doi: 10.1172/JCI85086. Epub 2016 Apr 11.

15.

A miR-192-EGR1-HOXB9 regulatory network controls the angiogenic switch in cancer.

Wu SY, Rupaimoole R, Shen F, Pradeep S, Pecot CV, Ivan C, Nagaraja AS, Gharpure KM, Pham E, Hatakeyama H, McGuire MH, Haemmerle M, Vidal-Anaya V, Olsen C, Rodriguez-Aguayo C, Filant J, Ehsanipour EA, Herbrich SM, Maiti SN, Huang L, Kim JH, Zhang X, Han HD, Armaiz-Pena GN, Seviour EG, Tucker S, Zhang M, Yang D, Cooper LJ, Ali-Fehmi R, Bar-Eli M, Lee JS, Ram PT, Baggerly KA, Lopez-Berestein G, Hung MC, Sood AK.

Nat Commun. 2016 Apr 4;7:11169. doi: 10.1038/ncomms11169.

16.

miR-509-3p is clinically significant and strongly attenuates cellular migration and multi-cellular spheroids in ovarian cancer.

Pan Y, Robertson G, Pedersen L, Lim E, Hernandez-Herrera A, Rowat AC, Patil SL, Chan CK, Wen Y, Zhang X, Basu-Roy U, Mansukhani A, Chu A, Sipahimalani P, Bowlby R, Brooks D, Thiessen N, Coarfa C, Ma Y, Moore RA, Schein JE, Mungall AJ, Liu J, Pecot CV, Sood AK, Jones SJ, Marra MA, Gunaratne PH.

Oncotarget. 2016 May 3;7(18):25930-48. doi: 10.18632/oncotarget.8412. Erratum in: Oncotarget. 2017 Mar 7;8(10 ):17406.

17.

Cancer's got nerve: Schwann cells drive perineural invasion.

Azam SH, Pecot CV.

J Clin Invest. 2016 Apr 1;126(4):1242-4. doi: 10.1172/JCI86801. Epub 2016 Mar 21.

18.

Role of Increased n-acetylaspartate Levels in Cancer.

Zand B, Previs RA, Zacharias NM, Rupaimoole R, Mitamura T, Nagaraja AS, Guindani M, Dalton HJ, Yang L, Baddour J, Achreja A, Hu W, Pecot CV, Ivan C, Wu SY, McCullough CR, Gharpure KM, Shoshan E, Pradeep S, Mangala LS, Rodriguez-Aguayo C, Wang Y, Nick AM, Davies MA, Armaiz-Pena G, Liu J, Lutgendorf SK, Baggerly KA, Eli MB, Lopez-Berestein G, Nagrath D, Bhattacharya PK, Sood AK.

J Natl Cancer Inst. 2016 Jan 26;108(6):djv426. doi: 10.1093/jnci/djv426.

19.

Germline Mutation of T790M and Dual/Multiple EGFR Mutations in Patients With Lung Adenocarcinoma.

Lou Y, Pecot CV, Tran HT, DeVito VJ, Tang XM, Heymach JV, Luthra R, Wistuba II, Zuo Z, Tsao AS.

Clin Lung Cancer. 2016 Mar;17(2):e5-11. doi: 10.1016/j.cllc.2015.11.003. Epub 2015 Nov 17. No abstract available.

20.

A genome-scale screen reveals context-dependent ovarian cancer sensitivity to miRNA overexpression.

Shields BB, Pecot CV, Gao H, McMillan E, Potts M, Nagel C, Purinton S, Wang Y, Ivan C, Kim HS, Borkowski RJ, Khan S, Rodriguez-Aguayo C, Lopez-Berestein G, Lea J, Gazdar A, Baggerly KA, Sood AK, White MA.

Mol Syst Biol. 2015 Dec 11;11(12):842. doi: 10.15252/msb.20156308.

Supplemental Content

Loading ...
Support Center